EPISODE · Dec 10, 2024 · 5 MIN
Day 3 Highlights from ASH 2024: Lymphoma Breakthroughs and Myeloma Insights
from Curie: Healthcare in Focus
Day 3 of ASH 2024 revealed groundbreaking findings: a 97% complete response rate for zilovertamab vedotin in diffuse large B-cell lymphoma, new insights into zanubrutinib’s efficacy in chronic lymphocytic leukemia, and promising survival data for belantamab mafodotin in multiple myeloma. Like what you hear? Download Curie from the App Store for more personalized healthcare content.
NOW PLAYING
Day 3 Highlights from ASH 2024: Lymphoma Breakthroughs and Myeloma Insights
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m